These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 30194190

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.
    Jurczak W, Bryk AH, Mensah P, Gałązka K, Trofimiuk-Müldner M, Wyrobek Ł, Sawiec A, Skotnicki AB.
    J Med Case Rep; 2016 May 14; 10(1):123. PubMed ID: 27178351
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
    Yang QX, Pei XJ, Tian XY, Li Y, Li Z.
    Diagn Pathol; 2012 Jan 19; 7():7. PubMed ID: 22260632
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G, German High-Grade Lymphoma Study Group.
    J Clin Oncol; 2017 Aug 01; 35(22):2515-2526. PubMed ID: 28525305
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2011 Oct 01; 12(11):1013-22. PubMed ID: 21940214
    [Abstract] [Full Text] [Related]

  • 13. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y, Li ZM, Shi YX, Xia ZJ, Jiang WQ, Huang HQ.
    Ai Zheng; 2009 Feb 01; 28(2):146-9. PubMed ID: 19550126
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.
    Am J Hematol; 2013 May 01; 88(5):400-5. PubMed ID: 23423884
    [Abstract] [Full Text] [Related]

  • 16. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE.
    Lancet Haematol; 2016 Jul 01; 3(7):e309-16. PubMed ID: 27374464
    [Abstract] [Full Text] [Related]

  • 17. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
    Kim YS, Ji JH, Ko YH, Kim SJ, Kim WS.
    Acta Haematol; 2014 Jul 01; 131(3):156-61. PubMed ID: 24192382
    [Abstract] [Full Text] [Related]

  • 18. [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
    Schneider T, Molnár Z, Deák B, Várady E, Tóth E, Csomor J, Matolcsy A, Lovey J, Lengyel Z, Petri K, Gaudi I, Rosta A.
    Orv Hetil; 2009 Nov 01; 150(44):2019-26. PubMed ID: 19861288
    [Abstract] [Full Text] [Related]

  • 19. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.
    J Clin Oncol; 2015 Jan 20; 33(3):251-7. PubMed ID: 25135992
    [Abstract] [Full Text] [Related]

  • 20. Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.
    Jakobsen LH, Bøgsted M, Brown PN, Arboe B, Jørgensen J, Larsen TS, Juul MB, Schurmann L, Højberg L, Bergmann OJ, Lassen T, Josefsson PL, Jensen P, Johnsen HE, El-Galaly TC.
    J Clin Oncol; 2017 Mar 20; 35(7):778-784. PubMed ID: 28095160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.